Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

Nine-month net loss narrowed, but operating losses increased as research and administrative expenses rose.

Rhea-AI Summary

Oculis (OCS) reported a third-quarter net loss of CHF 18.236 million while advancing its late-stage eye-disease and neurology pipeline. The loss widened from CHF 16.855 million a year earlier, while loss per share narrowed to CHF 0.30 from CHF 0.32. Cash, cash equivalents and short-term investments totaled $252.0 million at September 30, versus $268.7 million at December 31, 2025; the company expects funding to last into the second half of 2029.

Patient randomization is complete in Licaminlimab’s PREDICT-1 dry eye trial, with results expected around year-end 2026. Privosegtor’s PIONEER-1 optic neuritis trial is advancing enrollment, and new Phase 2 data showed lower neuronal-injury and inflammation biomarkers versus placebo. Oculis expects clearance to initiate acute multiple sclerosis relapse trials in Q4 2026. It also completed an asset purchase agreement with Accure Therapeutics for rights to Privosegtor and preclinical candidate ACT-02.

14 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 14 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointAccure Therapeutics asset purchase agreement completed, covering rights to Privosegtor and preclinical candidate ACT-02.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Cash resources of $252.0 million support the company’s expected runway into the second half of 2029.
• Moderate pointOrdinary-share sales under the existing at-the-market program provided proceeds that partially offset cash use.
• Moderate pointNine-month net loss narrowed to CHF 57.058 million from CHF 75.443 million in 2025.
• Minor point. Forward-looking: it has not happened yet and may not happen.Licaminlimab PREDICT-1 randomization is complete; topline results are expected around year-end 2026.

9 minor points

• Minor pointPrivosegtor PIONEER-1 is advancing site activation and enrollment in the United States and Europe.
• Minor pointPrivosegtor Phase 2 data showed lower neuronal-injury and inflammation biomarkers versus placebo.
• Minor pointPrivosegtor received positive FDA feedback supporting its regulatory pathway in acute multiple sclerosis relapses.
• Minor pointQ3 loss per share narrowed to CHF 0.30 from CHF 0.32 a year earlier.
• Minor pointNine-month loss per share narrowed to CHF 0.94 from CHF 1.48 in 2025.
• Minor pointNine-month warrant valuation adjustment generated a CHF 7.273 million gain, versus a CHF 9.056 million loss.
• Minor pointNine-month foreign exchange generated a CHF 3.742 million gain, versus a CHF 6.211 million loss.
• Minor pointTotal liabilities fell to CHF 23.566 million at September 30, from CHF 39.893 million at year-end 2025.
• Minor pointTotal equity rose to CHF 208.752 million at September 30, from CHF 196.070 million at year-end 2025.

Negative

• Moderate pointQ3 net loss widened to CHF 18.236 million from CHF 16.855 million a year earlier.
• Moderate pointNine-month operating loss widened to CHF 68.934 million from CHF 61.039 million in 2025.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Acute multiple sclerosis trial initiation awaits IND clearance, expected by Oculis in Q4 2026.
• Moderate pointOrdinary-share issuance under the at-the-market program dilutes existing shareholders.
• Minor pointCash and investments declined to CHF 210.3 million from CHF 213.0 million at December 31, 2025.

9 minor points

• Minor pointQ3 research expenses increased to CHF 15.054 million from CHF 14.117 million a year earlier.
• Minor pointQ3 administrative expenses increased to CHF 8.591 million from CHF 6.422 million a year earlier.
• Minor pointNine-month research expenses increased to CHF 44.383 million from CHF 43.797 million in 2025.
• Minor pointNine-month administrative expenses increased to CHF 25.077 million from CHF 18.030 million in 2025.
• Minor pointQ3 operating loss widened to CHF 23.638 million from CHF 20.296 million a year earlier.
• Minor pointQ3 grant income fell to CHF 7,000 from CHF 243,000 a year earlier.
• Minor pointNine-month grant income fell to CHF 526,000 from CHF 788,000 in 2025.
• Minor pointQ3 finance expense increased to CHF 371,000 from CHF 162,000 a year earlier.
• Minor pointNine-month finance expense increased to CHF 853,000 from CHF 592,000 in 2025.

News Explained

The report says proceeds from sales of ordinary shares under Oculis’ existing at-the-market program partly offset the cash decline; the program sells new shares gradually, so those sales increase the share count and reduce existing holders’ percentage ownership.

Argus Nov 4 session 13 alerts

-4.59% close to close 1.7x rel. volume Open Argus

Details

News Market Reaction – OCS

-6.8% Trough in 47 min

$450.82M Mkt Cap at Peak Alert

On Nov 4, the first trading day after this news, OCS closed 4.59% below the previous close. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner recorded 13 alerts for this stock that day. That session’s volume was 1.7x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Nov 4 session.

Key Figures

Cash and investments: $252.0 million Cash runway: Into 2H 2029 PREDICT-1 enrollment: 176 patients +5 more

Cash and investments

$252.0 million

As of September 30, 2026

Cash runway

Into 2H 2029

Company-reported runway

PREDICT-1 enrollment

176 patients

Randomized registrational symptoms trial

TNFR1 variant carriers

2/3 of enrolled patients

PREDICT-1

PREDICT-1 topline results

Around year-end 2026

Anticipated timing

IND clearance

Expected in Q4 2026

Trials in acute MS relapses

Visual function gains

+18 letters

Previously reported ACUITY results at Month 3

Net loss

$71.7 million

Nine months ended September 30, 2026; compared with $89.7 million in 2025

Previous Earnings Reports

1 past event · Latest: Aug 06

Same Type 1 event

1. Aug 06

   Q2 2026 earnings

   24h Move

   +2.4%

   Reported CHF 228.3 million in cash and runway into the second half of 2029.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

tnfr1, at-the-market offering, neurofilament light chain, glial fibrillary acidic protein

4 terms

tnfr1 medical

"TNFR1-mediated dry eye disease (DED)"

TNFR1 is a protein on the surface of many cells that acts like a lock for the inflammatory signal TNF‑alpha; when that signal fits the lock, it can flip cellular switches that trigger inflammation, cell death, or immune responses. Investors care because TNFR1 is a common drug target and biomarker: therapies that block or modulate it can treat inflammatory diseases or cancer, and changes in TNFR1 activity can affect a drug’s market potential and safety profile.

at-the-market offering financial

"sale of ordinary shares under the Company’s existing at-the-market offering program"

An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.

neurofilament light chain medical

"NfL (neurofilament light chain, a biomarker for neuronal injury)"

Neurofilament light chain is a protein released into cerebrospinal fluid and blood when nerve cells are damaged, acting like a measurable “leak” that signals injury to the brain or spinal cord. For investors, it matters because rising or falling levels can serve as an objective readout in clinical trials and disease monitoring, helping assess whether a drug or therapy is slowing nerve damage and reducing development or commercial risk.

glial fibrillary acidic protein medical

"GFAP (glial fibrillary acidic protein, a biomarker for CNS inflammation)"

Glial fibrillary acidic protein (GFAP) is a structural protein found mainly in certain brain cells; when those cells are damaged, GFAP can leak into blood or spinal fluid and be measured as a marker of brain injury or disease. Investors care because GFAP tests and therapies that affect GFAP levels are used in clinical trials, diagnostics, and regulatory decisions—think of GFAP like a smoke alarm that signals brain cell damage, which can influence market demand, approval timelines, and commercial prospects for medical products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated around year-end 2026.
• Privosegtor (PIONEER-1): Advancing global registrational trial in optic neuritis (ON), reinforced by new biomarker data supporting its neuroprotective potential. IND clearance to initiate trials in acute multiple sclerosis (MS) relapses is expected in Q4 2026.
• R&D Day scheduled for December 8, featuring a comprehensive update on the Company’s late-stage pipeline and insights from world-renowned experts in ophthalmology, neuro-ophthalmology, and neurology.
• Cash, cash equivalents, and short-term investments of $252.0 million as of September 30, 2026, providing cash runway into 2H 2029.

ZUG, Switzerland, November 3, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced results for the third quarter ended September 30, 2026, and provided an overview of the Company’s progress.

Riad Sherif, M.D., Chief Executive Officer of Oculis, stated: “The third quarter marked notable progress across our late-stage pipeline, advancing us towards several major value-driving milestones with significant opportunities to provide first-in-kind therapies and transform patient care in multiple neuro-ophthalmology and ophthalmology diseases. PREDICT-1 topline results are expected around year-end; if positive, they would position Licaminlimab to potentially become the first precision medicine in ophthalmology, specifically targeting TNFR1-mediated dry eye disease. I’m particularly encouraged by the continued momentum in Privosegtor PIONEER-1 registrational trial in optic neuritis, an indication backed by FDA Breakthrough Therapy designation and EMA Priority Medicines designation. Furthermore, the new translational biomarker data presented in the late-breaking abstract session at the ACTRIMS-ECTRIMS joint conference reinforced our rationale for expanding into broader neuro-axonal indications.”

In executing our neuro-ophthalmology strategy and in anticipation of IND clearance in acute multiple sclerosis relapses, we are solidifying Privosegtor as a broader neuroprotective franchise and adding essential disease and clinical development expertise with the appointments of experienced life sciences leaders: Prof. Björn Tackenberg, M.D., Ph.D. as Chief Scientific Officer and Aaron Tansy, M.D., as Vice President, Development Franchise Head, Neurology. Prof. Tackenberg joins Oculis from Roche, where he led Integrative Neuroscience & Medical Practice, overseeing clinical development strategy and execution, biomarker and evidence-generation initiatives, and strategic partnerships. Björn and Aaron are accomplished neurologists with proven track records in CNS and MS drug development. Our focus remains on translating Privosegtor clinical milestones into transformative therapies for patients and sustained, long-term value for our shareholders.

Recent Development Highlights and Upcoming Value-Driving Milestones:

Licaminlimab: Advancing the first potential precision medicine in ophthalmology, targeting TNFR1-mediated dry eye disease

• • Completed randomization in the PREDICT-1 registrational symptoms trial evaluating Licaminlimab as a precision medicine in TNFR-1-mediated DED, with topline results expected around year-end. The PREDICT-1 trial is a randomized, multi-center, double-masked, vehicle-controlled study that enrolled 176 patients, of whom 2/3 are patients who carry the TNFR1 genetic variant associated with an amplified clinical response to Licaminlimab in prior Phase 2 studies.
  • Approximately 10 million have moderate-to-severe disease requiring active treatment^1-2 with only ~13% of patients achieving sustained relief.³  An estimated 1.3 to 1.9 million individuals, carry the relevant TNFR1 genetic variant and could potentially benefit from Licaminlimab.^1,2,5,6 If approved, Licaminlimab has the potential to transform the treatment landscape by shifting from today’s trial-and-error approach to the first precision medicine for TNFR1-mediated DED.

Privosegtor: Building a potentially first-in-class neuroprotective franchise across neuro-ophthalmology and neurology

• • Advancing global site activation and enrollment in the global PIONEER-1 registrational trial in the United States and Europe, with an execution priority on key centers and on building multidisciplinary networks connecting emergency room physicians, ophthalmologists, and neurologists. This integrated approach is designed to optimize operational flows and capitalize on peak enrollment opportunities in fall, winter, and spring to align with the disease's natural seasonality.
  • Released new Phase 2 ACUITY biomarker data showing lower levels of plasma NfL (neurofilament light chain, a biomarker for neuronal injury) and GFAP (glial fibrillary acidic protein, a biomarker for CNS inflammation) with Privosegtor versus placebo. These new biomarker findings and translational analyses support previously reported functional (LCVA) +18-letter gains and structural retinal preservation at Month 3, reinforcing Privosegtor’s neuroprotective potential and its development for acute optic neuritis and acute multiple sclerosis relapses.
  • Received positive FDA feedback supporting the regulatory pathway for Privosegtor in acute MS relapses, leveraging existing Privosegtor data, with IND clearance expected in Q4 2026.
  • In the U.S. alone, it is estimated that well over 30,000 new cases of optic neuritis^7-8 and 170,000 MS relapses⁹ occur annually. Current treatment primarily addresses inflammation, with no approved neuroprotective therapies to prevent neuro-axonal damage and associated loss of function. If approved, Privosegtor could potentially be the first neuroprotective therapy for patients with acute optic neuritis and MS relapses to address this significant unmet medical need.

Corporate Development: Strengthening Oculis’ neuro-ophthalmology and neurology pipeline and capabilities

• Completed the asset purchase agreement with Accure Therapeutics for rights to Privosegtor (ACT-01) to enhance strategic flexibility and ownership of the asset while driving long-term value creation, and ACT-02, an early-stage preclinical neurology drug candidate. This transaction aims to fortify Oculis’ position as an emerging leading neuro-ophthalmology and neurology company.
• Strengthened Oculis’ neurology capabilities with the appointments of Prof. Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer and Aaron Tansy, M.D., as Vice President, Development Franchise Head, Neurology. The appointees add deep scientific, clinical development, MS and neuroimmunology expertise to advance Privosegtor’s PIONEER program into acute MS relapses and other neurological indications.

Q3 2026 Financial Highlights:

As of September 30, 2026, Oculis held cash, cash equivalents and short-term investments of CHF 210.3 million or $252.0 million, compared to CHF 213.0 million or $268.7 million as of December 31, 2025. The decrease reflects operating expenses incurred during the year and approximately $8.0 million currency fluctuation during the third quarter as a result of strengthening of USD against the Company’s reporting currency CHF. The decline was partially offset by proceeds from the sale of ordinary shares under the Company’s existing at-the-market offering program. Research and development expenses were CHF 15.1 million or $18.5 million for the three months ended September 30, 2026, compared to CHF 14.1 million or $17.6 million in the same period in 2025. General and administrative expenses were CHF 8.6 million or $10.6 million for the three months ended September 30, 2026, compared to CHF 6.4 million or $8.0 million in the same period in 2025. The increase in operating expenses was primarily driven by headcount-related costs, including share-based compensation expenses, to execute the Company’s strategy to be a leader in neuro-ophthalmology and beyond, as well as certain non-recurring corporate initiatives in 2026. The Company’s net loss was CHF 57.1 million or $71.7 million for the nine months ended September 30, 2026, compared to CHF 75.4 million or $89.7 million for the same period in 2025. The decrease was primarily due to the fair value gain on warrant liabilities in 2026 driven by decreased market value compared to the prior year, as well as a favorable foreign currency fluctuation resulting from U.S. dollar-denominated transactions and assets.

Key Upcoming Events:
Oculis management plans to host an in-person and virtual R&D Day on December 8, 2026 at the St. Regis New York to review the Company’s development pipeline, including Licaminlimab for TNFR1-mediated dry eye disease (DED) and the related PREDICT-1 registrational trial, updates on the PIONEER development program for Privosegtor in optic neuritis, non-arteritic anterior ischemic optic neuropathy (NAION) and acute MS relapses. To register for the event click here.

Investor Conferences:

• 3^rd Annual Guggenheim Healthcare Innovation Conference, Nov. 9-11, Boston, USA
• Stifel NYC Healthcare Conference Nov. 10-12, New York, USA
• LifeSci and Sofinnova Growth and Innovation Summit, Nov. 16, London, UK
• Piper Sandler 38^th Annual Healthcare Conference, Dec. 1-3, New York, USA
• 45^th Annual J.P. Morgan Healthcare Conference, Jan. 11-14, San Francisco, USA

Condensed Consolidated Statements of Financial Position (Unaudited)

(Amounts in CHF thousands)		As of September 30,		As of December 31,
		2026		2025
ASSETS
Non-current assets
Property and equipment		449		534
Intangible assets		13,292		13,292
Right-of-use assets		2,774		2,463
Other non-current assets		980		785
Total non-current assets		17,495		17,074
Current assets
Other current assets		2,919		4,883
Accrued income		1,613		993
Short-term financial assets		143,999		131,684
Cash and cash equivalents		66,292		81,329
Total current assets		214,823		218,889
TOTAL ASSETS		232,318		235,963
EQUITY AND LIABILITIES
Shareholders' equity
Share capital		681		587
Share premium		607,790		551,731
Reserve for share-based payment		43,526		30,387
Actuarial loss on post-employment benefit obligations		(1,290)		(1,634)
Treasury shares		(62)		(7)
Cumulative translation adjustments		(321)		(480)
Accumulated losses		(441,572)		(384,514)
Total equity		208,752		196,070
Non-current liabilities
Long-term lease liabilities		1,983		1,811
Defined benefit pension liabilities		938		1,335
Total non-current liabilities		2,921		3,146
Current liabilities
Trade payables		1,445		1,800
Accrued expenses and other payables		13,734		19,967
Short-term lease liabilities		803		502
Warrant liabilities		4,663		14,478
Total current liabilities		20,645		36,747
Total liabilities		23,566		39,893
TOTAL EQUITY AND LIABILITIES		232,318		235,963

Condensed Consolidated Statements of Loss (Unaudited)

		For the three months ended September 30,				For the nine months ended September 30,
(Amounts in CHF thousands, except per share data)
		2026		2025		2026		2025
Grant income		7		243		526		788
Operating income		7		243		526		788
Research and development expenses		(15,054)		(14,117)		(44,383)		(43,797)
General and administrative expenses		(8,591)		(6,422)		(25,077)		(18,030)
Operating expenses		(23,645)		(20,539)		(69,460)		(61,827)
Operating loss		(23,638)		(20,296)		(68,934)		(61,039)
Finance income		621		438		1,580		1,451
Finance expense		(371)		(162)		(853)		(592)
Fair value adjustment on warrant liabilities		3,156		3,089		7,273		(9,056)
Foreign currency exchange gain (loss)		1,954		89		3,742		(6,211)
Finance result		5,360		3,454		11,742		(14,408)
Loss before tax for the period		(18,278)		(16,842)		(57,192)		(75,447)
Income tax benefit (expense)		42		(13)		134		4
Loss for the period		(18,236)		(16,855)		(57,058)		(75,443)
Loss per share:
Basic and diluted loss attributable to equity holders		(0.30)		(0.32)		(0.94)		(1.48)

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com 

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotection therapy for optic neuritis and its potential broad applicability across neurology, including in acute MS relapses, and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach, the initiation, site activation, enrollment, execution approach, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; intended benefits of the asset purchase transaction with Accure Therapeutics; the timing or likelihood of regulatory filings and approvals; statements about market opportunity, including estimated DED patients with the relevant TNFR1 genetic variant; and statements about cash runway, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Results of earlier stage clinical trials may not be replicated in subsequent clinical trials. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

1. Jain H, et al. (2020): Dry eye disease landscape and forecast. Decision Resources Group (DRG). Prevalence for G7 countries: France, Germany, Italy, Japan, Spain, UK, and US.
2. GlobalData – Dry Eye Syndrome Global Drug Forecast and Market Analysis to 2026
3. Mukamal, R. Why is Dry Eye So Difficult to Treat? 2021 https://www.aao.org/eye-health/tips-prevention/fix-dry-eye-treatment-eyedrops
4. Mbagwu M. et al.: Characterization of Discontinuation and Switching Patterns of DED Medications Using Linked HER Registry and Claims Data. Presented at ASCRS Annual Meeting 2024.
5. Galor, A., et al. Licaminlimab in the treatment of dry eye disease: Results from Phase 2 evaluations. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
6. Acuna, Kelly & al. (2023). Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease. Biomolecules.
7. Weidong Gu et al. (2023) Incidence of Optic Neuritis and the Associated Risk of Multiple Sclerosis for Service Members of U.S. Armed Forces, Military Medicine, vol. 188, March/April 2023
8. Abbass, N.J., Shaia, J.K., Shukla, P. et al. Prevalence of pediatric and adult optic neuritis in the United States from 2016 to 2023. Eye 39, 1608–1614 (2025).
9. Relapse volume derived as ARR 0.2 × ~850,000 U.S. MS prevalence (Hauser SL, et al. N Engl J Med. 2020;383:546-557, Bigaut K, et al. J Neurol. 2022 Jun;269(6):3295-3300).

- ENDS-

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Oculis expect Licaminlimab PREDICT-1 results?

Oculis expects PREDICT-1 topline results around year-end 2026. Patient randomization is complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease.

How long does Oculis expect its cash to last after Q3 2026?

Oculis expects its cash runway to extend into the second half of 2029. Cash, cash equivalents and short-term investments totaled $252.0 million, or CHF 210.3 million, as of September 30, 2026.

How is Oculis conducting the Licaminlimab PREDICT-1 trial?

PREDICT-1 is a randomized, multi-center, double-masked, vehicle-controlled study that enrolled 176 patients. Two-thirds carry the TNFR1 genetic variant associated with an amplified clinical response to Licaminlimab in prior Phase 2 studies. Double-masked means patients and investigators do not know the assigned treatment.

Why did Oculis report a smaller nine-month net loss in 2026?

The smaller nine-month net loss primarily reflected a warrant valuation gain and favorable foreign currency movements. The warrant adjustment shifted to a CHF 7.273 million gain from a CHF 9.056 million loss, while foreign exchange shifted to a CHF 3.742 million gain from a CHF 6.211 million loss.

When is Oculis holding its pipeline R&D Day?

Oculis plans to hold an in-person and virtual R&D Day on December 8, 2026, at the St. Regis New York. The agenda includes Licaminlimab and PREDICT-1, plus Privosegtor’s PIONEER program in optic neuritis, non-arteritic anterior ischemic optic neuropathy and acute multiple sclerosis relapses.